Results 301 to 310 of about 3,431,393 (387)

Severe Vasoplegic Syndrome Treated with Angiotensin II and Hemoadsorption Therapy after Cardiac Surgery

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Vasoplegic syndrome (VS) is a common complication after cardiac surgery with cardiopulmonary bypass (CPB). The main pathophysiology mechanism of VS includes a systemic inflammatory response syndrome due to surgical trauma, release of pro‐inflammatory mediators caused by blood contact with foreign surfaces of heart‐lung machine (pump and tubing)
Matteo Lucchelli, Davide Tommaso Andreis, Mattia Gomarasca, Giovanni Mistraletti   +3 more
wiley   +1 more source

Electrophysiological End Point for Catheter Ablation of Atrial Fibrillation Initiated From Multiple Pulmonary Venous Foci

, 2000
Michel Haı̈ssaguerre, Pierre Jaı̈s, Dipen Shah, Stéphane Garrigue, Atsushi Takahashi, Thomas Lavergne, Mélèze Hocini, Jing Peng, R Roudaut, Jacques Clémenty   +9 more
openalex   +1 more source

Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges

Clinical Pharmacology &Therapeutics, EarlyView.
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing.
D. Max Smith, Michael P. Douglas, Christina L. Aquilante, Patricia A. Deverka, Beth Devine, Henry M. Dunnenberger, Philip E. Empey, Daniel L. Hertz, Andrew A. Monte, Ann M. Moyer, Jai N. Patel, Victoria M. Pratt, Loren Saulsberry, Stuart A. Scott, Deepak Voora, Erica L. Woodahl, Michelle Whirl‐Carrillo, Akinyemi Oni‐Orisan, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +18 more
wiley   +1 more source

Catheter ablation of atrial fibrillation in patients with cardiac amyloidosis and sarcoidosis: procedural findings and outcomes. [PDF]

Europace
Oraii A, Hanumanthu BKJ, Petzl A, Liao TW, Afzalian A, Rodriguez-Queralto O, Chaumont C, Spears J, Markman TM, Hyman MC, Tschabrunn CM, Guandalini G, Enriquez A, Shivamurthy P, Kumareswaran R, Deo R, Ferrari VA, Riley MP, Lin D, Callans DJ, Supple GE, Schaller RD, Frankel DS, Garcia FC, Nazarian S, Dixit S, Marchlinski FE.   +26 more
europepmc   +1 more source

Further Investigation Into an Environmental Source for Aminorex

Drug Testing and Analysis, EarlyView.
The results provide evidence that resedine is an intermediary compound between barbarin and aminorex in horses and that resedine can be used as a biomarker to eliminate the reporting of aminorex positives originating from the ingestion of plants from the Brassicaceae family.
Lydia Brooks, Michael Ryan, Erin McCosham, Devan Loganathan   +3 more
wiley   +1 more source

Administration Studies in Equine Antidoping Research: Designing Scientific Investigations to Effectively Direct Medication Control in Racehorses

Drug Testing and Analysis, EarlyView.
ABSTRACT Pharmacokinetics is the study of the movement of drug in the body and includes the processes of absorption, distribution, metabolism, and excretion. Pharmacodynamics is the pharmacologic effect of the drug on the body. The pharmacokinetics of a drug determines its pharmacologic effect. Pharmacokinetic studies describe drug concentrations while
Heather K. Knych
wiley   +1 more source

Effects of Dimenhydrinate on Motor Behavior and Vascular Function: Possible Implications for the Field of Sports

Drug Testing and Analysis, EarlyView.
Regarding cardiovascular effects, DMH decreased vascular reactivity to phenylephrine and acetylcholine. We observed that the combination of DPH and 8‐Cl‐T was identified as the responsible for increasing blood pressure and heart rate in the biological model used.
Jazmín Flores‐Monroy, Diana Ramírez‐Hernández, Diego Lezama‐Martínez, Benjamín Velasco‐Bejarano   +3 more
wiley   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Catheter Ablation Improves Ventilatory Efficiency in Atrial Fibrillation-Mediated Cardiomyopathy. [PDF]

J Cardiovasc Electrophysiol
Ahluwalia N, Bruce D, Ashdown A, Focacci F, Abbass H, Honarbakhsh S, Chow A, Dhinoja M, Hunter RJ, Petersen S, Lloyd G, Schilling RJ.   +11 more
europepmc   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source